INVEGA HAFYERA 1,560 MG/5 ML

What it is

INVEGA HAFYERA 1,560 MG/5 ML is how the CMS NADAC file names this product. The FDA NDC Directory lists it as paliperidone palmitate, under the trade name “INVEGA HAFYERA”.

FDA gives its dosage form as injection, suspension, extended release and its route as intramuscular.

The labeler, the company named on the label, is Janssen Pharmaceuticals, Inc.

FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 50458-0612-01.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $21,167.01 for 5 mL (5 × $4,233.40151 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-01-02. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-01-02. The file is new; the price is not.

What NADAC measures · NADAC explanation codes · Carried-forward prices

The NDC

• 50458-0612-01 · Janssen Pharmaceuticals, Inc · $4,233.40151 per ML · eff. 2026-01-02 filed carried forward

Other strengths, forms and brands

10 other products in the NADAC file share the FDA nonproprietary name paliperidone palmitate with INVEGA HAFYERA 1,560 MG/5 ML.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-02, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $4,233.40151 per ML filed.

Of the 25 other products in FDA’s Atypical Antipsychotic class priced per ML, 5 have a higher middle NADAC price and 20 a lower one. The one in the middle is INVEGA SUSTENNA 234 MG/1.5 ML, at $2,338.47458 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-02, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $20,718.05 for 5 mL, at an average of $4,143.61081 per ML in 2024 (2024-01-01 to 2024-12-31) for “Invega Hafyera” and “Paliperidone Palmitate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 5,856 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 5 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 5 mL; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.